Graybill Wealth Management LTD. Has $7.74 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Graybill Wealth Management LTD. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 12,506 shares of the medical research company’s stock after purchasing an additional 223 shares during the period. Thermo Fisher Scientific accounts for about 2.9% of Graybill Wealth Management LTD.’s portfolio, making the stock its 9th largest position. Graybill Wealth Management LTD.’s holdings in Thermo Fisher Scientific were worth $7,736,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Riverview Trust Co purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $81,000. Inspirion Wealth Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth $203,000. Sarasin & Partners LLP lifted its holdings in shares of Thermo Fisher Scientific by 10.5% during the 1st quarter. Sarasin & Partners LLP now owns 459,793 shares of the medical research company’s stock valued at $267,236,000 after purchasing an additional 43,678 shares during the last quarter. First Financial Corp IN grew its stake in Thermo Fisher Scientific by 1.4% during the 1st quarter. First Financial Corp IN now owns 2,136 shares of the medical research company’s stock worth $1,241,000 after buying an additional 30 shares during the last quarter. Finally, Prentice Wealth Management LLC increased its position in Thermo Fisher Scientific by 8.4% during the 1st quarter. Prentice Wealth Management LLC now owns 894 shares of the medical research company’s stock valued at $520,000 after buying an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TMO. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 target price for the company. Barclays increased their price target on shares of Thermo Fisher Scientific from $600.00 to $620.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 15th. Bank of America boosted their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $656.16.

Thermo Fisher Scientific Stock Down 1.3 %

TMO stock traded down $7.46 during midday trading on Tuesday, reaching $587.91. 397,535 shares of the company were exchanged, compared to its average volume of 1,458,800. The stock’s 50-day simple moving average is $607.91 and its 200 day simple moving average is $584.40. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $627.88. The company has a market cap of $224.58 billion, a price-to-earnings ratio of 36.93, a price-to-earnings-growth ratio of 3.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.15 earnings per share. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the sale, the vice president now owns 13,699 shares in the company, valued at approximately $8,397,760.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock valued at $14,094,292 over the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.